Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | CCKAR | P32238 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | GHSR | Q92847 | 2/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31742584 | 0.97 | PRMT1 (0.59) | PRMT1OPRD1OPRM1CCKARCCKBR | |
| SCHEMBL30272491 | 0.92 | GHSR (0.58) | ACEGHSRERAP2UTS2R | |
| SCHEMBL31741259 | 0.92 | PRMT1 (0.59) | PRMT1OPRD1CCKARCCKBRACE | |
| SCHEMBL29616865 | 0.89 | OPRD1 (0.64) | OPRD1OPRM1CCKARCCKBRGHSR | |
| SCHEMBL30728822 | 0.89 | GHSR (0.61) | ACEGHSRUTS2R | |
| SCHEMBL30605164 | 0.88 | ACE (0.59) | OPRD1OPRM1ACEERAP2 | |
| SCHEMBL31593270 | 0.88 | GHSR (0.58) | ACEGHSRUTS2R | |
| SCHEMBL31541502 | 0.88 | OPRM1 (0.55) | PRMT1OPRD1OPRM1ACEGHSR | |
| SCHEMBL30255956 | 0.87 | ACE (0.58) | PRMT1OPRD1OPRM1ACEERAP2 | |
| SCHEMBL30921655 | 0.86 | GHSR (0.60) | ACEGHSRERAP2UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340608-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12269856-B2 | Hepcidin analogues and uses thereof | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240174726-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-11807674-B2 | Hepcidin analogues and uses thereof | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4091624-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | Protagonist Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220348626-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269856-B2 | Hepcidin analogues and uses thereof | HAMP, SLC40A1, FTH1 | PRMT1 1682/4885OPRD1 2419/4885OPRM1 2209/4885 |
| US-11807674-B2 | Hepcidin analogues and uses thereof | HAMP, SLC40A1, FTH1 | PRMT1 1682/4885OPRD1 2419/4885OPRM1 2209/4885 |
| US-20250340608-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | PRMT1 1682/4885OPRD1 2419/4885OPRM1 2209/4885 |
| US-20240174726-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | PRMT1 1682/4885OPRD1 2419/4885OPRM1 2209/4885 |
| US-20220348626-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | PRMT1 1682/4885OPRD1 2419/4885OPRM1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.